Related Experiment Video

Updated: Jun 2, 2026

Proteomic Profile of EPS-Urine through FASP Digestion and Data-Independent Analysis
14:48

Proteomic Profile of EPS-Urine through FASP Digestion and Data-Independent Analysis

Published on: May 8, 2021

Urinary proteomics in cardiovascular disease: Achievements, limits and hopes

Christian Delles1, Javier Diez, Anna F Dominiczak

  • 1Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. christian.delles@glasgow.ac.uk

Proteomics. Clinical Applications
|April 28, 2011
PubMed

Insights

Urinary proteomics shows promise for diagnosing cardiovascular disease (CVD). This approach analyzes urine proteins, offering a less complex and non-invasive method for understanding CVD pathogenesis.

Area of Science:

  • Proteomics
  • Biomarker Discovery
  • Cardiovascular Medicine

Background:

  • Cardiovascular disease (CVD) is a leading global cause of death.
  • Current diagnostic and risk stratification methods for CVD face challenges.
  • Clinical proteomics offers a method to analyze numerous proteins in biofluids.

Purpose of the Study:

  • To review pilot studies on urinary proteomics in coronary artery disease.
  • To discuss the potential of urinary proteomics for CVD diagnosis and risk stratification.
  • To explore the role of urinary proteomics in understanding CVD pathogenesis.

Main Methods:

  • Analysis of urinary proteome.
  • Review of pilot studies in coronary artery disease.
  • Comparison of urinary and plasma proteome complexity.

Main Results:

  • The urinary proteome is less complex than the plasma proteome.
  • Urine collection is non-invasive, making it attractive for clinical applications.
  • Pilot studies suggest potential for urinary proteomics in CVD.

Conclusions:

  • Urinary proteomics is a promising field for CVD research.
  • Non-invasive urine analysis offers advantages over plasma-based methods.
  • Further research is needed to fully realize the potential of urinary proteomics in clinical practice.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Proteomics01:33

Proteomics

A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...